

Index

- AACAP. *See* American Academy of Child and Adolescent Psychiatry
- AAN. *See* American Academy of Neurology
- affective disorders, 20, 137, 144–145
- alpha-2 adrenergic medications
 for behavioural co-morbidities of Tourette syndrome, 6–7, 143, 144
- Clonidine, 88–93, 129–130, 131, 132–134, 138, 139, 140, 141, 143, 144, 146–147
- Guanfacine, 93–98, 132–134, 138, 139, 140, 141, 143, 144
- American Academy of Child and Adolescent Psychiatry (AACAP), Practice Parameter, 134–137
- American Academy of Neurology (AAN), 140–145
- antidopaminergic medications
 for behavioural co-morbidities of Tourette syndrome, 6–7
- first generation
 Fluphenazine, 37–42
 Haloperidol, 4, 43–49, 129, 130, 131, 140, 141, 143–144
 Pimozide, 49–54, 55, 129, 130, 131, 140, 141, 143–144
- historical introduction of, 4
- patient experiences with, 5, 138–140
- receptor subtypes acted on by, 26
- second generation
 Aripiprazole, 4, 5, 56–62, 129, 130, 131, 132–134, 140, 141, 143–144, 146–147, 148–149
- Olanzapine, 62–67, 132–134
- Quetiapine, 68–73, 74, 130, 131, 132–134
- Risperidone, 74–81, 129, 130, 131, 132–134, 140, 141, 143–144, 146–147, 148–149
- Ziprasidone, 81–87, 130, 131, 140, 141, 143–144
- secondary tics induced by, 17, 18–19
- anti-epileptic medications, 17, 18–19
- anxiety disorders, 20, 137, 144–145
- Aripiprazole
 adverse effects of, 57, 58–59
 behavioural neurology of, 61
 cautions for use of, 57, 58
 clinical indications of, 57
 dose titration of, 57
 guidelines on treatment of tics with, 61, 129, 130, 131, 132–134, 140, 141, 143–144, 146–147, 148–149
 historical introduction of, 4
 interactions of, 59–60
 overall rating/summary of efficacy and tolerability of, 62
 patient experiences with, 5, 138–140
 pharmacological properties of, 56
 preparations of, 56, 57
 special population recommendations for, 60
- Ascher, Eduard, 2–4
- athetosis, 19
- attention-deficit hyperactivity disorder, 6–7, 16, 21, 137, 143, 144
- autism spectrum disorders, 17–18, 22
- basal ganglia circuits, 25
- behavioral interventions, 136
- behavioural co-morbidities, 6–8, 16, 20–22, 136, 137, 143, 144–145
- brain injury, 17, 18
- breastfeeding. *See* pregnancy and breastfeeding
- C&A-GTS-QOL. *See* Gilles de la Tourette Syndrome-Quality of Life Scale
- Canada, pharmacotherapy guidelines published in, 131–134
- central nervous system stimulants, 17, 18–19
- CGI scale. *See* Clinical Global Impression scale
- Charcot, Jean-Martin, 1–2, 3
- chorea, 19
- chromosomal abnormalities, 17–18
- Claudius, 1
- clinical characteristics, tics, 9–14, 15
- Clinical Global Impression (CGI) scale, 32
- clinical judgement, 127
- Clonidine
 adverse effects of, 90
 behavioural neurology of, 92
 cautions for use of, 89
 clinical indications of, 89
 dose titration of, 89
 guidelines on treatment of tics with, 92, 129–130, 131, 132–134, 138, 139, 140, 141, 143, 144, 146–147
 interactions of, 91
 overall rating/summary of efficacy and tolerability of, 93
 pharmacological properties of, 88
 preparations of, 88

- Clonidine (cont.)
 special population
 recommendations
 for, 91
 communication, diagnosis,
 24–25
 complex tics, 9, 10–13
 compulsive tics, 20–21
 coprolalia, 1, 2–4, 9, 10
 copropraxia, 9, 10
 cortico-striato-thalamo-
 cortical circuits, 25
- da Vinci, Leonardo, 1
 Dampierre, Marquise de,
 1–2
 DCI. *See* Tourette Syndrome
 Diagnostic Confidence
 Index
 developmental stuttering,
 17–18
*Diagnostic and Statistical
 Manual* (DSM-5),
 14–16, 20
 diagnostic criteria of tic
 disorders, 14–16
 disruptive behaviour disorder,
 20, 137, 144–145
 dopaminergic
 neurotransmission,
 26
 dose titrations
 Aripiprazole, 57
 Clonidine, 89
 Fluphenazine, 38
 Guanfacine, 94
 Haloperidol, 44
 Metoclopramide, 100
 Olanzapine, 63
 Pimozide, 50
 Quetiapine, 68–69
 Risperidone, 75
 Sulpiride, 104
 Tetrabenazine, 110
 Tiapride, 114
 Topiramate, 120
 Ziprasidone, 82
 DSM-5. *See* *Diagnostic and
 Statistical Manual*
 dystonia, 19
- echolalia, 1, 2–4, 9, 10
 echopraxia, 9, 10
 environmental factors, in tics,
 16–17
 Eroom's Law, 4–5
- ESSTS. *See* European Society
 for the Study of
 Tourette Syndrome
 Europe, pharmacotherapy
 guidelines published in
 expert survey and consensus
 based, 146–147
 systematic literature review
 and meta-analysis
 based, 129–131
 European Society for the Study
 of Tourette Syndrome
 (ESSTS), 129–131,
 146–147
 evidence based medicine,
 127–128. *See also*
 systematic literature
 review and meta-
 analysis
 expert survey and consensus,
 pharmacotherapy
 guidelines based on
 Europe and UK (2012),
 146–147
 Japan (2019), 147–149
- family
 diagnosis communication
 with, 24–25
 natural history information
 for, 142
 psychoeducation for, 24–25,
 136, 142
 Feindel, Eugene, 2–4
 Ferenczi, Sándor, 2–4
 first-generation
 antidopaminergic
 medications. *See*
 antidopaminergic
 medications
 Fluphenazine
 adverse effects of, 39–40
 behavioural neurology of,
 41–42
 cautions for use of, 38, 39
 clinical indications of, 38
 dose titration of, 38
 guidelines on treatment of
 tics with, 42
 interactions of, 40–41
 overall rating/summary of
 efficacy and tolerability
 of, 42
 pharmacological properties
 of, 37
 preparations of, 38
- special population
 recommendations
 for, 41
 Freud, Sigmund, 2–4
- genetics, tics, 16–17
 Gilles de la Tourette, Georges,
 1–2, 3
 Gilles de la Tourette
 Syndrome–Quality of
 Life Scale (GTS-QOL,
 C&A-GTS-QOL),
 35–36
 Guanfacine
 adverse effects of, 95–96
 behavioural neurology of, 97
 cautions for use of, 94, 95
 clinical indications of, 94
 dose titration of, 94
 guidelines on treatment of
 tics with, 98, 132–134,
 138, 139, 140, 141,
 143, 144
 interactions of, 96–97
 overall rating/summary of
 efficacy and tolerability
 of, 98
 pharmacological properties
 of, 93
 preparations of, 94
 special population
 recommendations
 for, 97
 guidelines on
 pharmacotherapy
 alpha-2 adrenergic
 medications
 Clonidine, 92, 129–130,
 131, 132–134, 138, 139,
 140, 141, 143, 144,
 146–147
 Guanfacine, 98, 132–134,
 138, 139, 140, 141,
 143, 144
 expert survey and consensus
 based
 Europe and UK (2012),
 146–147
 Japan (2019), 147–149
 first-generation
 antidopaminergic
 medications
 Fluphenazine, 42
 Haloperidol, 48–49, 129,
 130, 131, 140, 141,
 143–144

- Pimozide, 54, 129, 130, 131, 140, 141, 143–144
- other tic-suppressing medications
- Metoclopramide, 103, 138, 139, 140, 141, 143–144
- Sulpiride, 108, 129, 130, 131
- Tetrabenazine, 113, 130, 131
- Tiapride, 118, 129, 130, 131, 140, 141, 143–144
- Topiramate, 124–125, 138, 139, 140, 141, 144
- second-generation antipdopaminergic medications
- Aripiprazole, 61, 129, 130, 131, 132–134, 140, 141, 143–144, 146–147, 148–149
- Olanzapine, 67, 132–134
- Quetiapine, 73, 74, 130, 131, 132–134
- Risperidone, 80–81, 129, 130, 131, 132–134, 140, 141, 143–144, 146–147, 148–149
- Ziprasidone, 86–87, 130, 131, 140, 141, 143–144
- systematic literature review and meta-analysis based, 127–128
- Canada (2012), 131–134
- Europe and UK (2011), 129–131
- UK (2016), 137–140
- US (2013), 134–137
- US (2019), 140–145
- habits, 19
- Haloperidol
- adverse effects of, 44, 45–46
- behavioural neurology of, 45
- cautions for use of, 44, 45
- clinical indications of, 44
- dose titration of, 44
- guidelines on treatment of tics with, 48–49, 129, 130, 131, 140, 141, 143–144
- historical introduction of, 4
- interactions of, 47
- overall rating/summary of efficacy and tolerability of, 49
- pharmacological properties of, 43
- preparations of, 43–44
- special population recommendations for, 47, 48
- health-related quality of life
- co-morbidity impact on, 6–8, 20
- rating scales for, 30, 35–36
- hepatic and renal impairment
- Aripiprazole use in patients with, 60
- Clonidine use in patients with, 91
- Fluphenazine use in patients with, 41
- Guanfacine use in patients with, 97
- Haloperidol use in patients with, 47
- Metoclopramide use in patients with, 102
- Olanzapine use in patients with, 65, 66
- Pimozide use in patients with, 52, 53
- Quetiapine use in patients with, 73
- Risperidone use in patients with, 79, 80
- Sulpiride use in patients with, 107
- Tetrabenazine use in patients with, 112
- Tiapride use in patients with, 117
- Topiramate use in patients with, 123
- Ziprasidone use in patients with, 83, 86
- history taking, 22–24
- Howard, Tim, 5
- Hughlings-Jackson, John, 1–2
- Huntington disease, 17, 18
- impulsive tics, 21
- Individualized PUTS (I-PUTS), 34–35
- Itard, Jean, 1–2
- Japan, pharmacotherapy guidelines published in, 147–149
- Levodopa, 17, 18–19
- Mahler, Margaret, 2–4
- Malleus Maleficarum*, 1
- Meige, Henri, 2–4
- meta-analysis. *See* systematic literature review and meta-analysis
- Methylphenidate, 18–19
- Metoclopramide
- adverse effects of, 101
- behavioural neurology of, 103
- cautions for use of, 100
- clinical indications of, 100
- dose titration of, 100
- guidelines on treatment of tics with, 103, 138, 139, 140, 141, 143–144
- interactions of, 102
- overall rating/summary of efficacy and tolerability of, 103, 104
- pharmacological properties of, 99
- preparations of, 99, 100
- special population recommendations for, 102
- Motor Tic, Obsessions and Compulsions, Vocal Tic Evaluation Survey (MOVES), 29–31
- motor tics, 9, 10–12, 13–14
- Movement Disorder Society, 20
- movement disorders
- psychogenic, 17, 19
- tic differential diagnosis from, 19
- MOVES. *See* Motor Tic, Obsessions and Compulsions, Vocal Tic Evaluation Survey
- myoclonus, 19
- neuroacanthocytosis, 17, 18
- neurochemical systems, in pathophysiology of Tourette syndrome, 26
- neurodegeneration with brain iron accumulation, 17, 18
- neurodegenerative diseases, secondary tics in, 17, 18
- neurodevelopmental disorders, secondary tics in, 17–18
- neurological co-morbidities, 20

- obsessive-compulsive disorder, 6–7, 16, 20–21, 137, 144
- Olanzapine
 adverse effects of, 63, 64–65
 behavioural neurology of, 66–67
 cautions for use of, 63, 64
 clinical indications of, 63
 dose titration of, 63
 guidelines on treatment of tics with, 67, 132–134
 interactions of, 65, 66
 overall rating/summary of efficacy and tolerability of, 67
 pharmacological properties of, 62
 preparations of, 63
 special population recommendations for, 65, 66
- other specified tic disorder, 14–16
- paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), 16–17
- palilalia, 9, 10
- palipraxia, 9, 10
- PANDAS. *See* paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections
- pathophysiology, tics, 22–27
- persistent motor tic disorder, 14–16
- persistent vocal tic disorder, 14–16
- pharmacotherapy. *See also* guidelines on pharmacotherapy; *specific medications*
 efficiency of research and development of, 4–5
 evidence based, 127–128
 historical introduction of, 4
 natural history considerations in, 142
 patient experiences with, 5, 138–140
- rational approach to, 7–8, 26–27
- receptor subtypes acted on by, 26
- reference selection for, 6, 7
- tics induced by, 17, 18–19
- phonic tics, 9, 12–14
- Pimozide
 adverse effects of, 51, 52
 behavioural neurology of, 54
 cautions for use of, 51
 clinical indications of, 50
 dose titration of, 50
 guidelines on treatment of tics with, 54, 129, 130, 131, 140, 141, 143–144
 interactions of, 51, 53
 overall rating/summary of efficacy and tolerability of, 54, 55
 pharmacological properties of, 49, 50
 preparations of, 49, 50
 special population recommendations for, 52, 53
- placebo effect, 128
- pregnancy and breastfeeding
 Aripiprazole use during, 60
 Clonidine use during, 91
 Fluphenazine use during, 41
 Guanfacine use during, 97
 Haloperidol use during, 47, 48
 Metoclopramide use during, 102
 Olanzapine use during, 66
 Pimozide use during, 52, 53
 Quetiapine use during, 73
 Risperidone use during, 80
 Sulpiride use during, 107
 Tetrabenazine use during, 112
 Tiapride use during, 117
 Topiramate use during, 123, 124
 Ziprasidone use during, 85, 86
- Premonitory Urge for Tics Scales (PUTS), 34–35
- premonitory urges, 9, 19
- rating scales for, 30, 34–35
- primary tic disorders, 14–16.
See also Tourette syndrome
- provisional tic disorder, 14–16
- psychiatric co-morbidities, 6–8, 16, 20–22, 136, 137, 143, 144–145
- psychoanalytic theories of tics, 2–4
- psychoeducation, 24–25, 136, 142
- psychogenic movement disorders, 17, 19
- psychometric instruments. *See* rating scales
- PUTS. *See* Premonitory Urge for Tics Scales
- quality of life. *See* health-related quality of life
- Quetiapine
 adverse effects of, 70–72
 behavioural neurology of, 73
 cautions for use of, 70
 clinical indications of, 69
 dose titration of, 68–69
 guidelines on treatment of tics with, 73, 74, 130, 131, 132–134
 interactions of, 72
 overall rating/summary of efficacy and tolerability of, 73, 74
 pharmacological properties of, 68
 preparations of, 68, 69
 special population recommendations for, 73
- rating scales, 28
- premonitory urges, 29, 34–35
- proposed psychometric battery, 28, 30
- quality of life, 29, 35–36
- tic severity, 29–33
- rational pharmacotherapy, 7–8, 26–27
- receptors, anti-tic medication effects on, 26
- renal impairment. *See* hepatic and renal impairment
- Risperidone
 adverse effects of, 76, 77–79
 behavioural neurology of, 80
 cautions for use of, 75, 76
 clinical indications of, 75, 76
 dose titration of, 75

- guidelines on treatment of tics with, 80–81, 129, 130, 131, 132–134, 140, 141, 143–144, 146–147, 148–149
- interactions of, 79
- overall rating/summary of efficacy and tolerability of, 81
- pharmacological properties of, 74, 75
- preparations of, 75
- special population recommendations for, 79, 80
- second-generation antidopaminergic medications. *See* antidopaminergic medications
- secondary tic disorders, 17–19
- Shapiro, Arthur and Elaine, 4
- Shapiro Tourette Syndrome Severity Scale (STSS), 31
- stereotypies, 22
- stimulants, 17, 18–19
- STSS. *See* Shapiro Tourette Syndrome Severity Scale
- Sulpiride
- adverse effects of, 106–107
 - behavioural neurology of, 108
 - cautions for use of, 105
 - clinical indications of, 105, 107
 - dose titration of, 104
 - guidelines on treatment of tics with, 108, 129, 130, 131
 - overall rating/summary of efficacy and tolerability of, 108, 109
 - pharmacological properties of, 104
 - preparations of, 104, 105
 - special population recommendations for, 107
- systematic literature review and meta-analysis, pharmacotherapy guidelines based on, 127–128
- Canada (2012), 131–134
- Europe and UK (2011), 129–131
- UK (2016), 137–140
- US (2013), 134–137
- US (2019), 140–145
- tardive dyskinesias, 17, 18–19
- Tetrabenazine
- adverse effects of, 111
 - behavioural neurology of, 113
 - cautions for use of, 110
 - clinical indications of, 110
 - dose titration of, 110
 - guidelines on treatment of tics with, 113, 130, 131
 - interactions of, 112
 - overall rating/summary of efficacy and tolerability of, 113
 - pharmacological properties of, 109
 - preparations of, 109, 110
 - special population recommendations for, 112
- Tiaprside
- adverse effects of, 115, 116
 - behavioural neurology of, 117
 - cautions for use of, 115
 - clinical indications of, 114, 115
 - dose titration of, 114
 - guidelines on treatment of tics with, 118, 129, 130, 131, 140, 141, 143–144
 - interactions of, 116, 117
 - overall rating/summary of efficacy and tolerability of, 118
 - pharmacological properties of, 114
 - preparations of, 114
 - special population recommendations for, 117
- tic disorders. *See also* Tourette syndrome
- natural history of, 142
 - as neuropsychiatric disorders, 20
 - primary, 14–16
 - secondary, 17–19
- tics
- assessment and
- quantification of, 28
 - proposed psychometric battery, 28, 30
 - rating scales for premonitory urges, 30, 34–35
 - rating scales for quality of life, 30, 35–36
 - rating scales for tic severity, 29–33
- classification of, 9
- co-morbid behavioural symptoms with, 6–8, 16, 20–22, 136, 137, 143, 144–145
- co-morbid neurological symptoms with, 20
- definition of, 9
- evaluation and differential diagnosis of
- clinical characteristics, 9–14, 15
 - diagnostic criteria of tic disorders, 14–16
 - differential diagnosis of tics and co-morbid conditions, 16–22
 - pathophysiology and treatment approaches, 22–27
- evidence-based medicine for, 127–128
- factors alleviating or exacerbating, 13
- genetic and environmental factors in, 16–17
- historical perspective on, 1–5
- history taking in, 22–24
- introduction of
- pharmacological agents in treatment of, 4
 - medication research and development for, 4–5
- motor, 9, 10–12, 13–14
- motor manifestations resembling, 19
- onset of, 13–14
- patient experiences with medications for, 5, 138–140
- psychoanalytic theories of, 2–4
- rational pharmacotherapy for, 7–8, 26–27
- severity of, 29–33

- tics (cont.)
 vocal, 9, 12–14
- TODS. *See* Tourette's Disorder Scale
- Topiramate
 adverse effects of, 120, 121–122
 behavioural neurology of, 123–124
 cautions for use of, 120
 clinical indications of, 120
 dose titration of, 120
 guidelines on treatment of tics with, 124–125, 138, 139, 140, 141, 144
 interactions of, 123
 overall rating/summary of efficacy and tolerability of, 125
 pharmacological properties of, 118, 119
 preparations of, 119
 special population recommendations for, 123, 124
- Tourette syndrome
 behavioural co-morbidities of, 6–8, 16, 20–22, 136, 137, 143, 144–145
 current definition of, 1
 diagnosis communication in, 24–25
 efficiency of medication research and development for, 4–5
 evaluation and differential diagnosis of clinical characteristics, 9–14, 15
 diagnostic criteria of tic disorders, 14–16
 differential diagnosis of tics and co-morbid conditions, 16–22
 pathophysiology and treatment approaches, 22–27
- evidence based medicine for, 127–128
- genetic and environmental factors in, 16–17
- historical perspective on, 1–5
- history taking in, 22–24
- introduction of pharmacological agents in treatment of, 4
- natural history of, 142
- neurological co-morbidities of, 20
- as neuropsychiatric disorder, 20
- patient experiences with medications for, 5, 138–140
- prevalence of, 13
- psychoanalytic theories of, 2–4
- psychoeducation for, 24–25, 136, 142
- rating scales for, 28
 premonitory urges, 30, 34–35
 proposed psychometric battery, 28, 30
 quality of life, 30, 35–36
 tic severity, 29–33
- rational pharmacotherapy for, 7–8, 26–27
- reference selection for, 6, 7
- Tourette Syndrome Diagnostic Confidence Index (DCI), 14, 15
- Tourette Syndrome–Clinical Global Impression (TS-CGI), 32
- Tourette's Disorder Scale (TODS), 31–32
- toxins, tics induced by, 17, 18–19
- treatment approaches, tics, 22–27. *See also* pharmacotherapy
- tremor, 19
- Trousseau, Armand, 1–2
- TS-CGI. *See* Tourette Syndrome–Clinical Global Impression
- UK, pharmacotherapy guidelines published in expert survey and consensus based, 146–147
 systematic literature review and meta-analysis based, 129–131, 137–140
- US, pharmacotherapy guidelines published in 2013, 134–137
 2019, 140–145
 unspecified tic disorder, 14–16
- vocal tics, 9, 12–14
- Wilson disease, 17, 18
- Yale Global Tic Severity Scale (YGTSS), 33
- Ziprasidone
 adverse effects of, 82, 83, 84–85
 behavioural neurology of, 86
 cautions for use of, 82, 83
 clinical indications of, 82, 83
 dose titration of, 82
 guidelines on treatment of tics with, 86–87, 130, 131, 140, 141, 143–144
 interactions of, 83, 85
 overall rating/summary of efficacy and tolerability of, 87
 pharmacological properties of, 81, 82
 preparations of, 82
 special population recommendations for, 83, 85, 86